EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 juil. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals to Highlight DURAVYU™ (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
26 juin 2024 08h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 –– Positive...
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
18 juin 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
17 juin 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
05 juin 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 mai 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
08 mai 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– Company on track to initiate the Phase 3 LUGANO pivotal non-inferiority trial of DURAVYU™ in wet AMD in 2H 2024 – – $299 million of cash and investments on March 31, 2024, with cash runway through...
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
06 mai 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
– DURAVYU demonstrates stable or improved disease severity with reduced rates of NPDR progression at nine months – – DURAVYU continues to demonstrate favorable safety and tolerability profile with no...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
16 avr. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of...
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
02 avr. 2024 07h00 HE
|
EyePoint Pharmaceuticals, Inc.
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board –- Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O,...